You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Nationwide epidemiological study of neuromyelitis optica in Japan
  1. Katsuichi Miyamoto1,
  2. Kazuo Fujihara2,
  3. Jun-ichi Kira3,
  4. Nagato Kuriyama4,
  5. Makoto Matsui5,
  6. Akiko Tamakoshi6,
  7. Susumu Kusunoki1
  1. 1 Department of Neurology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan
  2. 2 Department Multiple Sclerosis and Therapeutics, Fukushima Medical University, Koriyama, Japan
  3. 3 Department of Neurology, Kyusyu University, Fukuoka, Japan
  4. 4 Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
  5. 5 Department of Neurology, Kanazawa Medical University, Ishikawa, Japan
  6. 6 Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  1. Correspondence to Professor Susumu Kusunoki, Department of Neurology, Faculty of Medicine, Kindai University, Osaka-Sayama 589-8511, Japan; kusunoki-tky{at}umin.ac.jp

https://doi.org/10.1136/jnnp-2017-317321

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Neuromyelitis optica (NMO) is characterised by severe optic neuritis and transverse myelitis. In contrast to multiple sclerosis (MS), there have been few large-scale epidemiological surveys of NMO. The worldwide prevalence of NMO is estimated to be 1 in 100 000. NMO may be more prevalent in Asia, Africa and Latin America than in Europe and North America. NMO has been well recognised following the discovery of anti-aquaporin 4 (AQP4) antibody, and highly sensitive and specific cell-based assays using AQP4 antibody are widely available in Japan. Based on previous literature, we planned and performed the first-ever nationwide epidemiological study of NMO in Japan, which has a population of about 130 million. An advantage of performing a nationwide survey in Japan is that the Japanese archipelago stretches for 3500 km from north to south (45°−24° N). As the north–south gradient for the prevalence of MS is an important epidemiological finding reported in Japan and other countries, Japan is an ideal country to study potential differences in the prevalence of NMO associated with changes in latitude.

    Method

    We conducted a nationwide survey on NMO in clinical departments using established epidemiological methods in 20111. The survey was performed at departments of neurology, internal medicine, paediatrics, neurosurgery, orthopaedics, ophthalmology and psychiatry based on random selection using a stratified sampling method. Although the diagnostic criteria for NMO were …

    View Full Text

    Linked Articles